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or lenalidomid regimen and cross-sectionally 45.07%/24.73%/8.51% were treated 
by lenalidomid/bortezomib/conventional chemotherapy regimens, mean time to 
progression was 0.81 year. In the 5th line-34.19%/18.36%/18.36% of patients were 
treated by lenalidomid/bortezomib/conventional chemotherapy regimens, mean-
time to progression was 0.88 years. In the 6th line-60.20% of patients were treated 
by conventional chemotherapy. ConClusions: This cross-sectional survey deter-
mined the prevalence and treatment strategies of MM patients in Slovakia accord-
ing to the treatment lines.
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objeCtives: To estimate health care resource use (HCRU) associated with the 
advanced melanoma management in Portugal and to calculate the resulting direct 
medical and non-medical costs. Methods: An expert panel with 6 clinicians from 
the main Portuguese centers treating patients with advanced melanoma was cre-
ated and assessed to estimate HCRU associated with the disease management. A 
two-stage modified Delphi technique was adopted. During the 1st round experts 
answered to a questionnaire concerning resource consumption associated with 
different phases of disease management. At the 2nd round experts discussed and 
validated the mean results obtained from the questionnaires, during a consensus 
meeting. Phases of disease considered were: treatment initiation, progression 
free, post-progression and terminal care. HCRU during progression free phase 
was estimated for two different subsets of patients, according to their previous 
treatment experience: ipilimumab-naïve patients and ipilimumab previously 
treated patients. Medical appointments, laboratory tests, imaging examinations, 
hospitalizations, radiotherapy/radiosurgery and concomitant medications were 
the resources considered. HCRU resulting from adverse events management was 
not included. Costs for each phase were obtained by multiplying mean estimates 
of HCRU by unit costs according to official sources. Oncology drugs costs were 
not included during the treatment phase. Results: Elicited costs per disease 
management phase were the following: 893.4 € for treatment initiation, 1280.4€ /3 
weeks and 1487.5€ /3 weeks for treatment phase, respectively for ipilimumab-naïve 
and ipilimumab previously treated patients. For the BSC phase the cost estimated 
was 1668.7 € /month and the total terminal care cost was 5920.8€ . ConClusions: 
Inpatient costs assumed major role during all phases (except treatment initiation). 
Patient monitoring through medical appointments, laboratory tests and imaging 
examinations had a higher share of resource consumption during treatment phase 
than for patients on BSC. The results from our research are of utmost importance 
to support the cost-effectiveness evaluation of new advanced melanoma treat-
ment strategies.
CANCer – Patient-reported outcomes & Patient Preference studies
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objeCtives: Adherence to oncologic treatment is a key factor to improve the 
survival of oncologic patients. Several clinical trials reveal non-adherence in these 
patients is common, affecting the health results negatively. The objective is to 
review the published evidence about adherence to oncologic treatment. Methods: 
Systematic review of published articles in PubMed about adherence to oncological 
treatments (January 2005-December 2014) in the European Union. Article selection 
by two independent investigators was based on title and abstract. In addition to 
the incapability to meet other inclusion criteria, the little quality of the results 
was ground for exclusion of a single article. Articles were classified according 
to trial design, type of cancer and adherence measurement method. Results: 
27 publications were analyzed, in which adherence data was described for nine 
different types of cancer and breast cancer was the most studied (51.9% of the 
articles). United Kingdom was the country that carried out the most clinical tri-
als (40.7%). 92.6% of the articles evaluated the adherence of female cohorts and 
48.2% evaluated both men and women cohorts. The most employed methodologies 
to measure adherence were Self-Report, MPR (Medication Possession Ratio) and 
MEMSTM (Electronic Medication Event Monitoring System). 7.4% of the articles 
reported adherence results, 48.2% of adherent to treatment patients and 44.4% of 
both. Adherence ranges fluctuated between 25.9% and 100% while the ranges of 
adherent patients oscillated between 7.84% and 92%. Age was one of the factors 
that affected adherence to oncological treatments (patients under 60 and over 75 
were less adherent to oncological treatments). ConClusions: Disparity in cri-
teria and measurement methods contributes to the great heterogeneity of adher-
ence and adherent patients published data. The poor adherence levels retrieved 
confirm the need of implementing healthcare interventions to foster adherence, 
given its impact on both oncological treatments effectiveness and healthcare 
systems sustainability.
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objeCtives: Electronic data capture of patient-reported outcomes (ePRO) offers effi-
ciency, greater accuracy and improved compliance vs paper. However, mode equiva-
lence and device usability needs to be demonstrated, per ISPOR ePRO Research 
1Kantar Health, Montrouge, France, 2Hôpital Morvan - CHU de Brest, BREST, France, 3Hôpital 
Albert Michallon - CHU de Grenoble, LA TRONCHE, France, 4MSD France, COURBEVOIE, France, 
5MSD France, Courbevoie, France, 6Hôpital Dupuytren - CHU de Limoges, LIMOGES, France, 
7Amaris, Paris, France
objeCtives: The objective of the AMEL study was to describe healthcare resource 
utilization (HCRU) among advanced melanoma patients according to the treat-
ment they received in order to assess the mean cost per line of therapy according 
to the treatment received. Methods: The study was a retrospective observa-
tional study using medical records. 33 physicians participated in the research. 
Each physician documented all of their patients diagnosed with advanced cuta-
neous melanoma between January 1st 2012 and October 31st 2012. Resource use 
related to hospitalizations, outpatient visits, radiotherapy and imaging tests 
were collected throughout the patient pathway, from diagnosis to end of the data 
extraction or death, whichever occurred first. The costing was based on ENCC 
reference costs. Results: After exclusion of the patients whose treatment was 
part of a clinical trial, HCRU could be assessed for 220 patients who received 1st 
line treatment, 144 2nd line and 67 3rd line. Hospital consumption increased 
together with the line of therapy. The proportion of patients experiencing at least 
one hospitalization was 46.4%, 50.7% and 62.7% in 1st, 2nd and 3rd line and the 
mean length of stay was 14,39, 15.6 and 17.3 days respectively. In 1st line, the main 
cause of hospitalization was treatment administration (41.2% of patients) while 
it was palliative care in 2nd and 3rd line (52.1% and 54.8%). Hospitalization due to 
treatment toxicities occurred in 18.6% of first line patients, with a mean length of 
stay of 20.21 days and was less frequent in 2nd and 3rd line (6.8 and 9.5%). After 
valorization, the mean hospital cost per patient was 1,526€ in 1st line, 2,098€ in 
2nd and 2,250€ in 3rdline. ConClusions: Health care consumption, including 
hospitalization, increased together with evolution of the disease, with the most 
costly period being the “terminal state”.
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objeCtives: Subcutaneous versions of different oncology therapies are available 
since few years for which the patient-relevant and hospital benefits have not been 
assessed in real life. Methods: In order to analyze the impact of subcutaneous 
administrations for rituximab or trastuzumab in comparison to the respective intra-
venous mode a primary research in Italy was executed. The study’s primary objec-
tives were to analyze the resource and cost implications from different perspectives 
(patient, medical staff) in real world. The route of administration was discussed 
and aligned with the participating centers in order to capture all relevant therapy 
parts. After the successful execution of a pilot study 33 centers in 6 regions in 
Italy were recruited to participate. Results: Significant time savings are achieved 
with the subcutaneous mode through significantly lower patient preparation time 
including less time preparing the actual dosing for each individual patient. The total 
time difference is 3.3 hours with rituximab in hematology (NHL) which adds up to 
23.55 hours for a full course of treatment per patient (overall preparation time: 40.1 
hours intravenous [95%CI: +0.47] vs 16.6 hours subcutaneous [95%CI: +0.2]). In early 
breast cancer (trastuzumab) the time saving is 3.3 hours for the first cycle and the 
total time saving for patient preparation is 17.2 hours (overall preparation time: 
38.8 hours intravenous [95%CI: +9.42] vs 21.6 hours subcutaneous [95%CI: +9.9]). 
Furthermore in both settings the time of medical stuff was reduced and could hence 
be used elsewhere. Finally in case wastage was experienced with intravenous thera-
pies there were significant reductions in wastage through the subcutaneous admin-
istration (93% to 100%) with cost savings of 6’057 € with rituximab subcutaneous 
and 28’399 € with trastuzumab subcutaneous administration, respectively for the 
full treatment course. ConClusions: There are significant resource and cost sav-
ings due to subcutaneous administration with rituximab and trastuzumab in Italy.
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objeCtives: The latest official national data on epidemiology of multiply mye-
loma (MM) are available for year 2008. Estimated incidence for 2015 represents in 
both sexes 311 cases (age-standardized (ASR-W) incidence 3.1/100,000), mortality 
176 cases (ASR-W 1.6/100,000), prevalence 1,715 patients. The objective of this 
cross-sectional survey was to define prevalence and treatment strategies used in 
MM patients according to the treatment lines and provide a basis for the budget 
impact analysis (BIA). Methods: Data on treatment of 656 MM patients from 7 
MM-centers in 2013 from whole Slovakia were collected and analyzed. Continuous 
variables were calculated using standard descriptive statistics methods Results: 
86.9% of patients were cross-sectionally on active treatment. In the 1st clinical 
stage (according to Durie and Salmon classification) were 13.03% of patients, in 
the 2nd clinical stage-32.07%, in the 3rd clinical stage-54.09%. The treatment 
strategies were as followed: In the 1st line-36.34% of patients underwent BMT, 
outside them 80.53% were on bortezomib regimen, mean-time to progression rep-
resented 2.31 years. In the 2nd line-22.83% (out of 36.34%) of patients underwent 
re-transplant, outside them 68.50% were on lenalidomid regimen, mean-time to 
progression was 1.65 years. In the 3rd line-42.84%/21.71%/12.97% of patients were 
on bortezomib/lenalidomid/bendamustine regimens, mean-time to progression 
represented 1.29 year. 40.88% of all registered patients were in 2013 treated by 
the 4th line, 90.45% out of them had previously been treated by bortezomib and/
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A467
mean estimates in QALYs in favour of vinflumine can be quite different depending 
on how censored patients are handled especially when proportion of censoring 
differs by treatment group.
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objeCtives: The present study used long-term EQ-5D scores to evaluate patients 
with metastatic breast cancer (MBC) in a randomized control trial (RCT). Methods: 
Patients with HER2-negative MBC were randomly allocated to the S-1 (an oral fluo-
ropyrimidine) or taxane (paclitaxel or docetaxel) group. The primary endpoint was 
overall survival (OS), and QOL was a secondary endpoint. EQ-5D scores were sur-
veyed at pre-treatment, three months after randomization, and every six months 
thereafter. Mean scores were assessed by repeated measured ANOVA including 
baseline, group, time and interaction of group and time. Minimal important dif-
ference (MID) analysis was also performed by defining the MID of EQ-5D as 0.05 
or 0.1. When MID analysis was applied to the score during fist-line therapy, pro-
gression was treated as a competing risk. Results: A total of 618 patients with 
MBC were randomly allocated to both groups (N= 309 each). S-1 was non-inferior to 
taxanes for OS (median OS: S-1, 35.0 months; taxanes, 37.2 months). The number 
of patients in the EQ-5D population was 208 and 175 in S-1 and taxane groups, 
respectively. Mean duration of the EQ-5D response was 21 months for both groups. 
Mean EQ-5D scores up to 60 months were 0.748 and 0.741 in S1 and taxane groups, 
respectively. No significant difference was observed by ANOVA or MID analysis. 
During first-line therapy, mean EQ-5D score was 0.810 and 0.781 in S-1 and taxane 
groups up to 36 months, although in the post-progression period, scores decreased 
to 0.729 and 0.703, respectively. Gray’s test revealed that S-1 significantly delayed 
the decrease in QOL score. The size of the MID (0.05 or 0.1) did not influence the 
results. ConClusions: This study analyzed long-term EQ-5D scores of patients 
with MBC from RCT data. The QOL score of S-1 was higher during first-line therapy.
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objeCtives: Discrete choice experiments (DCE) are an important method for 
capturing data on the patient preferences. Neuroendocrine tumors (NET) are a rare 
disease and therefore a sufficient number of study participants for preference 
studies is difficult to recruit. Moreover there is hardly any international stand-
ard for the determination of the appropriate number of study participants in 
DCEs. Amongst others, suggestions on sample size have been made by Orme 
and Louviere. Methods: Patient-relevant outcomes concerning alternative 
treatment options of NET were weighted using a DCE including six attributes. 
Akaike information criterion (AIC), and Bayesian information criterion (BIC) 
together with the standard error (SE) were used to check the model fit and to 
determine the most appropriate sample size. For the sensitivity analysis dif-
ferent participants were randomly drawn from the study sample. Results: 
N= 275 NET-patients (48.5% male, mean age 58.4 years) could be included. With 
the maximum number of included participants all six attributes resulted in sig-
nificant values (p< 0.05). This sample sizes then accounts for an AIC= 3901.391, 
BIC= 4043.999 and a mean standard error (SE) of 0.057. Within the analysis an 
increasing sample size linearly improves the model fit. When including N= 30 
the mean SE does not fit the given 0.05 level (0.173). This improves with a higher 
sample size. Consequently, including N= 90 results in a mean SE below 0.1 with 
BIC= 4043.999 and AIC= 3901.391. The mean SE falls to 0.065 when including N= 210 
(BIC= 3169.285; AIC= 3032.256) ConClusions: Using the sensitivity analysis it can 
be shown that the model fit improves proportionally. An optimal sample size could 
therefore be approximated. Based on the preliminary results it is evident that with 
the given design and the given number of attributes and level a total N of at least 
275 participants is appropriate to conduct a DCE.
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objeCtives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing 
malignant tumors. So far there are no data on the patient preferences regarding the 
therapy of NET. This empirical study aimed at the elicitation of patient preferences 
in the drug treatment of NET. Methods: Based on qualitative patient interviews 
and an AHP, patient-relevant outcomes were analyzed and weighted using a discrete 
choice experiment (DCE). Six patient-relevant attributes were included. Patients 
were recruited with the help of a NET support group. For the DCE an experimental 
design (3*3 + 3*6 Design) was created using Ngene. The selected design consisted of 
84 choices, which were divided into 7 blocks. Participants were randomly assigned to 
these blocks. The analysis of DCE included random parameter logit models, condi-
tional logit models, and latent class models. Results: N = 275 NET-patients (51.6% 
female, mean age 58.4 years) participated. Under the chosen decision model the 
preference analysis within the random parameter logit model, taking into account 
Guidelines. Mode equivalence between paper and electronic versions of the EORTC 
Quality of Life Questionnaire (EORTC QLQ-C30;v3.0) and its Breast Cancer Module 
(QLQ-BR23;v1.0) was evaluated, as well as their usability on two electronic devices 
with different screen sizes. Methods: Adult women with metastatic breast cancer 
(mBC) who had not received chemotherapy for metastatic disease were screened. 
Using an alternating crossover study design, half completed questionnaires on paper 
first, followed by a tablet (10.1″screen) and a handheld (4.5″screen); the other half 
used the handheld first, followed by tablet and paper. To optimize recall, the think-
aloud method was used and cognitive debriefing interviews were conducted after 
each questionnaire was completed on each device. Usability questions were asked 
after completion of both questionnaires on a device. Results: 10 mBC patients 
were interviewed. Most patients reported that their answers would not differ on 
paper vs devices (tablet:C30= 70%;BR23= 100%), (handheld:C30= 90%;BR23= 90%). 
No participants attributed potential differences to interpreting items differently 
on the different modalities. 100% easily accessed questionnaires on the devices, 
understood instructions and easily moved from question-to-question. 90% were 
satisfied with the touchscreens, and all noted they could use either device inde-
pendently. Patients preferred the tablet vs handheld due to its larger screen; yet 
all preferred the handheld’s one-question-per-screen presentation, which allowed 
for greater focus. All patients indicated that screen size did not influence usability 
and that either device was acceptable to complete questionnaires. ConClusions: 
This study demonstrated mode equivalence between paper and electronic versions 
of EORTC-C30 and BR23, as well as between two devices. The devices were equally 
acceptable, providing evidence for their usability to collect PRO information from 
similar patients in clinical trials.
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objeCtives: Nonadherence to hormonal therapy is known to impact health out-
comes in patients with breast cancer. We measured nonadherence to aromatase 
inhibitors using a novel, clinic-based patient-reporting system. Methods: Patients 
of The West Cancer Center (Memphis, TN) were surveyed in the clinic prior to a 
scheduled appointment using the Patient Care Monitor system, a tablet-based, 
patient-reported outcomes platform. Adults diagnosed with breast cancer and 
prescribed an aromatase inhibitor were eligible to participate. The survey included 
30 questions and used three established instruments, including the Morisky 
Medication Adherence Scale and Medication Adherence Reasons Scale. The survey 
polled patients on their adherence to aromatase inhibitors, reasons for nonadher-
ence, and health literacy. Results: Over the course of 45 days, 3016 patients were 
self-screened for eligibility and interest; 1105 indicated interest; and 110 patients 
were fully eligible and completed the survey. Respondents were well-distributed 
by medication: anastrazole (42.2%), exemestane (33.9%), and letrozole (23.9%). 
Most patients (82.6%) reported being fully adherent (missed 0 days) in the past 
week; however, only 67.9% reported high adherence (score = 4) according to the 
Morisky Medication Adherence Scale (Spearman rho= -0.457, p-value< 0.0001). 
Mean adherence values or days missed did not differ significantly by medication 
or health literacy level. Among patients who reported missing at least one day in 
the previous week, the most often cited reasons were: simply missing the dose 
(44.4%), having problems forgetting things (38.9%), and concerns about side effects 
(33.3%). ConClusions: Adherence to hormonal therapy remains suboptimal and 
determining reasons for nonadherence prior to scheduled visits may assist provid-
ers in guiding patients. Moreover, the clinic’s Patient Care Monitor system is a novel 
patient engagement platform to collect patient-reported adherence data outside 
of the medical encounter, and may be leveraged to provide adherence and toxicity 
information to the healthcare team in real time.
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objeCtives: Utility analyses have previously been conducted for the Phase III 
trial of vinflunine (VFL) versus best supportive care (BSC) for the treatment of 
advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU). 
Results were presented according to progression status. The present study aims 
to calculate quality-adjusted life years (QALYs) for each patient and summarise 
results by treatment group. Methods: QALYs were calculated by patient using 
the area under the curve technique. Assumptions included that changes between 
utility measures over time were linear and utility at the time of death is zero. 
Once QALYs were calculated for all patients, univariate summaries were produced 
for both treatments separately considering different scenarios based on when 
baseline was recorded and how censored patients are handled in the QALY cal-
culation. The mean differences between treatments were evaluated using p-value 
derived from a two sample t-test and non-parametric Wilcoxon rank sum test. 
An analysis of covariance (ANCOVA), adjusting for baseline utility, was also per-
formed. Results: A total of 242 patients from the VFL and 103 from the BSC group 
had utility data and were eligible for the study. All BSC patients were observed to 
die, whilst 6% of VFL patients were censored and required imputation of death 
for QALY calculation. The estimated mean difference in QALY between treatment 
groups always favoured vinflunine regardless of method of analysis. Point esti-
mate ranged between -0.152 to -0.061. ANCOVA analyses move the point estimate 
slightly more in favour of vinflunine compared with unadjusted analyses. This 
was expected as the baseline utility was higher in the BSC group (0.781) compared 
to vinflunine (0.766). ConClusions: Sensitivity analyses show that difference 
